Skip to content
Log in
Sponsored Design Multi-Agent AI Systems Using MCP and A2A: Engineer your own Pyt Design Multi-Agent AI Systems Using MCP and A2A: Engineer your own Pyt

Low-dose prasugrel versus clopidogrel for dual antiplatelet therapy after percutaneous coronary intervention: insights from the STOPDAPT-2 total cohort.

T. Isawa Hirotoshi Watanabe Takeshi Morimoto M. Natsuaki Ko Yamamoto Y. Obayashi Kenji Ando Satoru Suwa Kohichiroh Ono K. Kadota Takanari Fujita Ruka Yoshida Hiroki Sakamoto M. Akao Yoshiki Hata Takeshi Kimura
Oct 2026 · Cardiovascular Intervention and Therapeutics · 0 citations · 10 references
Medicine

TL;DR

No significant differences were detected in short-term cardiovascular or bleeding outcomes between low-dose prasugrel-based and clopidogrel-based DAPT in patients after PCI without major in-hospital complications.

DOI PubMed Semantic Scholar
View source

Similar papers

Aug 2026

Clopidogrel or Dual Antiplatelet Therapy in High-Ischemic-Risk Patients.

Among patients at high risk for ischemic events 12 months after drug-eluting stent implantation, clopidogrel monotherapy was noninferior to extended DAPT with respect to net adverse clinical events at 24 months.

Seung-Jun Lee, Yong-Joon Lee, Kyounghoon Lee et al. · 0 citations
Open access Oct 2026

The Impact of Dual Antiplatelet Therapy on Bleeding and Thrombotic Risks in Diabetic Patients Following Coronary Stent Implantation: A Prospective Study.

AIMS To evaluate the 12-month clinical outcomes of short-term versus extended dual antiplatelet therapy (DAPT) in diabetic patients following drug-eluting stent (DES) implantation. METHODS In this single-center prospective cohort study, 536 diabetic patients undergoing DES implantation were categorized into short-ter...

R. Fan, Yu-Long Ma · 0 citations
Open access Oct 2026

Ticagrelor versus prasugrel following PCI in acute coronary syndromes and high-risk coronary artery disease: A meta-analysis of one-year randomized trial outcomes

Background Guidelines recommend potent P2Y12 inhibitors over clopidogrel following percutaneous coronary intervention. Whether ticagrelor- or prasugrel-based dual antiplatelet therapy (DAPT) provides superior clinical outcomes following percutaneous coronary intervention (PCI) remains uncertain, particularly across acu...

M. Gbreel, A. Badran, Daniel Robinson et al. · 1 citation
Open access Aug 2026

Early discontinuation of dual antiplatelet therapy after PCI in patients at high bleeding risk: an OCT-guided clinical case

The application of OCT for the evaluation of stent strut endothelialization provides a robust rationale for shortening DAPT duration to 1 month in patients with high hemorrhagic risk, even in the presence of concomitant diabetes mellitus and multiple comorbidities.

A. Prokhorikhin, Yu. V. Kukushkina, D. D. Zubarev et al. · 0 citations
Sep 2026

Low-dose ticagrelor combined with aspirin for preventing early neurological deterioration in patients with high-risk non-disabling ischemic cerebrovascular events: a multicenter, prospective, randomized, open-label, clinical trial

Among patients with HR‑NICE within 24 h of onset, low‑dose ticagrelor plus aspirin significantly decreased the incidence of END within 7 days and improved neurological functional outcomes at 90 days compared with clopidogrel plus aspirin, without increasing the risk of bleeding.

Jia-Hui Liu, Hua Cao, Ming-Li Wang et al. · 0 citations
Aug 2026

Aspirin Omission at the Time of Primary Percutaneous Coronary Intervention in STEMI.

BACKGROUND The safety of omitting up-front treatment with aspirin during primary percutaneous coronary intervention (PCI) in patients with ST-segment elevation myocardial infarction (STEMI) remains unclear. METHODS We conducted a multicenter, open-label, randomized trial in Japan involving patients with STEMI who wer...

Kuniaki Takahashi, Ken Kozuma, Yoshihiro Morino et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.